You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Therapeutic Intermittent Compression Socket

    SBC: Liberating Technologies, Inc.            Topic: N/A

    The purpose of this project is to develop a device that provides rapid intermittent compression to the residual limb of amputees that do not have good blood flow in their limbs. The device will be built into the prosthetic socket to provide the user with portable therapy throughout the day, which will free the user from being confined to a chair for up to six hours each day to receive the prescrib ...

    SBIR Phase I 2014 Department of Education
  2. A Novel Small Molecule Therapeutic for Alcoholic Chronic Pancreatitis

    SBC: Angion Biomedica Corp.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Chronic Pancreatitis (CP) is characterized by continuous or recurrent inflammation of the pancreas that leads to permanent destruction of the pancreas resulting in exocrine and endocrine insufficiency. CP is a common disorder associated with significant morbidity and mortality with an incidence of 8.2 and a prevalence of 27.4 per 100 000 population. The etiolog ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Gap Junction Inhibition Therapy for Alcoholic Liver Disease

    SBC: HEPROTECH, INC.            Topic: NIAAA

    ? DESCRIPTION (provided by applicant): Alcoholic liver disease is a highly prevalent and costly condition affecting millions of people globally. Alcohol results in high morbidity and mortality an is responsible for nearly 4% of all deaths worldwide. Despite the tremendous societal and economic burden, there is no approved therapeutics for alcoholic liver disease. Instead, the standard of care ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Clinically suitable approach for gene-mediated therapy of cirrhosis.

    SBC: ADVANTAGENE, INC            Topic: NIAAA

    Abstract Persistent injury to the liver can cause chronic inflammation and dysregulated deposition of extracellular matrix (ECM), leading to accumulation of fibrotic scar tissue and eventually cirrhosis. While fibrosis is a normal wound healing response, in excess, it can further injure tissue and activate pro-fibrotic cells, resulting in a positive feedback loop. Scar tissue is not static, ECM re ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Algorithm for Free Testosterone Determination

    SBC: Function Promoting Therapies, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): The measurement of testosterone levels is central to the diagnosis of androgen disorders in men and women. Circulating testosterone is bound largely to sex hormone binding globulin (SHBG) and albumin; only the unbound or free fraction is biologically active. Therefore, in conditions that affect SHBG concentrations, such as aging, obesity, and diabetes, the dete ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. PRECLINICAL TESTING OF HUMAN GHRELIN AND GROWTH HORMONE FOR SEPSIS IN THE ELDLY

    SBC: THERASOURCE, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): The ultimate goal of our proposal is to develop a novel therapeutic approach that will save lives of aged septic patients. Sepsis is the most common cause of death in the non-cardiac intensive care units (ICU). It is particularly a serious problem in the geriatric population. The elderly (e 65 years of age) accounts for 12% of the US population but 65% of sepsi ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Compounds for Reducing Brain A-Beta Levels via Enhanced Systemic Clearance

    SBC: Akston Biosciences Corporation            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is characterized by progressively worsening dementia eventually leading to death. It affects over five million people in the United States and costs the healthcare system over 200 billion per year. Currently there is no available therapy for slowing, reversing or preventing the disease. There is strong evidence suggesting that AD ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development, Production and Testing of VLP based Respiratory Syncytial Virus (RSV

    SBC: TechnoVax, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop a safe and efficacious virus-like particle (VLP) based-respiratory syncytial virus (RSV) vaccine to prevent the disease caused by this pathogen. The respiratory illnesses provokedby RSV in infants, children and the elderly are of global economical and public health impact. A recent worldwide estimate [5] indicates that ov ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. A Culture-Free Platform for Rapid Pathogen Identification

    SBC: HELIXBIND INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): A Culture-Free Platform for Rapid Pathogen Identification Project Summary Sepsis is a one of the leading causes of morbidity and mortality in the US, with more than 751,000 confirmed cases occurring every year and 210,000 mortalities. This high mortality rate (~30%) means that nearly 600 patients a day succumb to sepsis-related infections. In addition to the hu ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Novel therapeutic for hematopoietic stem cell regeneration in bone marrow post my

    SBC: Minerva Biotechnologies Corporation            Topic: NIAID

    DESCRIPTION (provided by applicant): The purpose of this study is to establish in vivo proof of principle for a human therapeutic for hematopoietic stem cell regeneration in the bone marrow after myeloablation from radiation. Blood stem cells are the mostsusceptible to the effects of radiation and the most lethal. We have already demonstrated proof of principle for our therapeutic in vitro. If suc ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government